About one in ten people will experience a seizure at some point in their lives, yet only 43% to 61% of those individuals go on to receive a diagnosis of new-onset epilepsy, according to a brief research report published in Frontiers in Molecular Biosciences. The gap between a single, unprovoked seizure and the beginning of epilepsy is one of the most consequential uncertainties in neurology, because the existing tools for telling the two apart are inadequate and often lead to treatment with antiseizure medications that may prove unnecessary. A team based at the Earle A Chiles Research Institute and Providence St Vincent Medical Center in Portland explored whether molecules circulating in blood could help close that diagnostic gap.
The researchers analyzed cell-free circulating microRNA expression in plasma samples from 20 patients who had presented with a first unprovoked seizure. MicroRNAs are small regulatory RNA molecules that circulate outside cells, and their expression patterns can shift in disease states, which has made them a frequent focus of biomarker research. Each patient in the study was monitored for two years following the initial seizure. During that follow-up period, a total of 7 patients experienced a second seizure, while the remaining 13 did not, allowing the investigators to compare molecular profiles between the two outcomes.
The comparison revealed 15 differentially expressed miRNAs between patients who experienced only a first unprovoked seizure and those who went on to have a second seizure within the two-year window. In other words, the expression levels of these 15 molecules in plasma drawn at the time of the initial event differed measurably between the two groups. The study was explicitly framed as exploratory, and the sample size of 20 patients, split into groups of 7 and 13, is small by any standard of clinical biomarker research. The authors themselves positioned the findings as targets that may be further developed as a biomarker signature in larger cohorts rather than as a test ready for clinical use.
To understand what these circulating molecules might be doing, the team turned to bioinformatics. The 15 differentially expressed miRNAs were experimentally linked, as regulators, to 160 genes related to epilepsy. This regulatory mapping matters because microRNAs do not typically act alone; each one can influence the expression of many downstream genes, and a change in a handful of miRNAs can therefore ripple across entire biological pathways. Among the genes connected to the 15 miRNAs were genes involved in the mTOR and WNT signaling pathways, both of which have established relevance in epilepsy research and in the cellular processes thought to underlie the development of epilepsy after an initial insult.
The clinical problem the study addresses is substantial. When a person arrives after a first unprovoked seizure, clinicians must weigh the risk of recurrence against the side effects and burdens of antiseizure medication, and the report notes that existing methods to distinguish between a first unprovoked seizure and a diagnosis of epilepsy are inadequate. This inadequacy often leads to unnecessary treatment with antiseizure medications, exposing patients who would never have had a second seizure to drugs they do not need. A blood-based biomarker that could stratify risk at the time of the first seizure would therefore be clinically valuable, which is precisely the motivation for examining cell-free circulating miRNAs in plasma.
The design of the study reflects that motivation. By sampling plasma at the point of the first unprovoked seizure and then following patients for two years, the investigators created a prospective structure in which the molecular measurements preceded the clinical outcome. The 7 patients who experienced a second seizure within the follow-up period effectively met a criterion consistent with a diagnosis of new-onset epilepsy, while the 13 who did not represent the isolated first-seizure group. The 15 miRNAs that separated these groups constitute a candidate signature, one that the authors suggest may offer insights into factors associated with epileptogenesis, the biological process that converts a single seizure into a chronic seizure disorder.
Several caveats frame the significance of the work. The cohort comprised 20 patients, and the number of outcome events, 7 second seizures, is small enough that chance findings cannot be excluded without replication. The article was published as a brief research report in the journal’s section on Molecular Diagnostics and Therapeutics, a format that signals the preliminary nature of the analysis. The authors describe the findings as highlighting key circulating miRNA targets that may be further developed as a biomarker signature in larger cohorts, an explicit acknowledgment that validation in independent and larger patient groups is the necessary next step before any diagnostic application could be contemplated.
Even so, the study adds a concrete, testable hypothesis to a field that urgently needs one. If the 15-miRNA signature can be reproduced in larger cohorts, and if its association with recurrence holds, clinicians could eventually have a molecular tool to complement clinical judgment when deciding whether to initiate antiseizure medication after a first unprovoked seizure. The regulatory links to mTOR and WNT pathway genes also give epilepsy researchers a defined set of molecular leads to pursue in studies of epileptogenesis. For now, the finding stands as an early signal from a small exploratory analysis: molecules measurable in plasma at the moment of a first seizure may carry information about whether epilepsy will follow, and the task of confirming that signal now moves to larger studies.
Subject of Research: Cell-free circulating miRNA expression as a candidate biomarker for distinguishing isolated first seizure from new-onset epilepsy
Article Title: Exploratory analysis of cell-free miRNA expression changes in patients with isolated first seizure and new-onset epilepsy
Article References: Meng, R. C., Lesko, A., Robinson, F., Baraban, E., Darke, K. H., Piening, B. D., & Fertig, E. J. (2026). Exploratory analysis of cell-free miRNA expression changes in patients with isolated first seizure and new-onset epilepsy. Frontiers in Molecular Biosciences, 13, 1788160. https://doi.org/10.3389/fmolb.2026.1788160
Image Credits: AI Generated
DOI: 10.3389/fmolb.2026.1788160
Keywords: new-onset epilepsy, first unprovoked seizure, cell-free miRNA, plasma biomarker, epileptogenesis, mTOR signaling, WNT signaling, bioinformatics, neurology, antiseizure medications, exploratory study, Frontiers in Molecular Biosciences
News Source: Kendall Mcintyre. (October 30, 2026). Circulating miRNAs may flag who develops epilepsy after a first seizure. Scienmag.
